URMC Research Network

Find People
Keyword
Last Name
 
More Search Options

Alan Katz

Concepts (149)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of pubs Most recent pub Pubs by all authors Concept score Why?
Radiosurgery
9
2006
73
1.960
Why?
Liver Neoplasms
7
2006
149
1.730
Why?
Neoplasm Metastasis
5
2006
219
1.020
Why?
Carcinoma, Hepatocellular
2
2011
68
0.950
Why?
Liver Transplantation
1
2011
246
0.640
Why?
Dose Fractionation
6
2006
57
0.480
Why?
Tumor Burden
4
2006
22
0.450
Why?
Neoplasms, Second Primary
3
1996
124
0.440
Why?
Lung Neoplasms
6
2000
422
0.440
Why?
Retrospective Studies
11
1997
2167
0.430
Why?
Breast Neoplasms
4
2000
660
0.430
Why?
Aged
22
1996
6986
0.420
Why?
Radiotherapy
2
2000
179
0.400
Why?
Aged, 80 and over
15
1997
2423
0.390
Why?
Middle Aged
21
1996
9461
0.380
Why?
Vagina
1
2001
51
0.370
Why?
Endometrial Neoplasms
1
2001
36
0.370
Why?
Brachytherapy
4
2000
108
0.360
Why?
Uterine Cervical Neoplasms
1
2001
125
0.350
Why?
Neoplasms, Radiation-Induced
1
2000
80
0.330
Why?
Skin Neoplasms
5
1996
225
0.330
Why?
Carcinoma, Merkel Cell
4
1996
10
0.320
Why?
Female
23
1996
19061
0.310
Why?
Hodgkin Disease
1
2000
152
0.310
Why?
Adult
20
1996
10906
0.290
Why?
Neoplasm Recurrence, Local
4
2000
272
0.290
Why?
Antineoplastic Combined Chemotherapy Protocols
4
1997
409
0.290
Why?
Humans
29
1996
35000
0.280
Why?
Treatment Outcome
9
1997
2487
0.270
Why?
Brain Neoplasms
3
2006
254
0.270
Why?
Stereotaxic Techniques
2
2006
32
0.270
Why?
Whole-Body Irradiation
2
2006
78
0.260
Why?
Male
19
1996
18870
0.230
Why?
Waiting Lists
1
2011
12
0.200
Why?
Cholangiocarcinoma
1
2012
13
0.200
Why?
Bone Neoplasms
3
2006
180
0.200
Why?
Airway Obstruction
2
2000
34
0.200
Why?
Necrosis
1
2011
99
0.190
Why?
Organ Size
1
2011
189
0.190
Why?
Radiotherapy Dosage
6
2000
185
0.190
Why?
Neoplasm Staging
3
2001
326
0.180
Why?
Feasibility Studies
2
2006
189
0.160
Why?
Remission Induction
2
2003
155
0.160
Why?
Neoplasms
2
1999
701
0.160
Why?
Sarcoma, Kaposi
2
1998
15
0.160
Why?
Thoracic Neoplasms
1
2009
17
0.160
Why?
Rectal Neoplasms
1
2010
82
0.160
Why?
Adrenal Gland Neoplasms
1
2009
35
0.160
Why?
Gene Expression Regulation, Neoplastic
1
2011
247
0.160
Why?
Carcinoma, Squamous Cell
2
2006
230
0.160
Why?
Radiation Injuries
2
2006
123
0.150
Why?
Survival Rate
4
2009
584
0.150
Why?
Cognition Disorders
1
2011
262
0.150
Why?
Liver
1
2011
870
0.140
Why?
Glioma
1
2008
92
0.140
Why?
Adenocarcinoma
2
2006
431
0.140
Why?
Prospective Studies
4
2008
1606
0.130
Why?
Follow-Up Studies
4
2003
1757
0.120
Why?
Tumor Markers, Biological
1
2006
221
0.110
Why?
Survival Analysis
5
1996
575
0.110
Why?
Pilot Projects
3
2008
426
0.110
Why?
Lymphatic Metastasis
4
1997
137
0.100
Why?
Etoposide
2
1997
73
0.100
Why?
Fluorouracil
2
1997
77
0.100
Why?
Bronchial Diseases
1
2001
10
0.100
Why?
Radiodermatitis
1
2001
8
0.090
Why?
Lung Diseases, Obstructive
1
2001
42
0.090
Why?
Constriction, Pathologic
1
2001
75
0.090
Why?
Sesquiterpenes
1
2001
19
0.090
Why?
Dermatologic Agents
1
2001
24
0.090
Why?
Medical Records
1
2001
122
0.090
Why?
Palliative Care
2
1999
151
0.090
Why?
Umbilicus
1
2000
4
0.090
Why?
Fatty Acids
1
2001
95
0.090
Why?
Abdominal Neoplasms
1
2000
14
0.090
Why?
Cholecystectomy
1
2000
17
0.090
Why?
Lipids
1
2001
164
0.090
Why?
Gallbladder Neoplasms
1
2000
8
0.090
Why?
Nucleic Acid Synthesis Inhibitors
1
2000
11
0.090
Why?
Anti-Inflammatory Agents, Non-Steroidal
1
2001
89
0.090
Why?
Antimetabolites, Antineoplastic
1
1999
38
0.080
Why?
Prognosis
3
1997
1030
0.080
Why?
Carcinoma
1
2000
188
0.080
Why?
Double-Blind Method
2
2010
985
0.070
Why?
Laparoscopy
1
2000
187
0.070
Why?
Melanoma
1
1999
133
0.070
Why?
Dose-Response Relationship, Radiation
2
2006
205
0.070
Why?
Treatment Failure
2
2006
125
0.070
Why?
Multivariate Analysis
3
1997
487
0.070
Why?
Israel
3
1996
30
0.060
Why?
Cisplatin
3
1997
93
0.060
Why?
Analysis of Variance
2
1997
705
0.050
Why?
Tomography, X-Ray Computed
2
2006
729
0.050
Why?
Sarcoma
1
2011
59
0.050
Why?
Head and Neck Neoplasms
1
2011
78
0.050
Why?
Esophageal Neoplasms
1
2011
76
0.050
Why?
Interleukin-8
1
2011
108
0.040
Why?
Medical Illustration
1
2010
10
0.040
Why?
Radiation Oncology
1
2010
17
0.040
Why?
Radiotherapy, Conformal
1
2010
18
0.040
Why?
Chemokine CCL2
1
2011
124
0.040
Why?
Colorectal Neoplasms
1
2011
138
0.040
Why?
Observer Variation
1
2010
137
0.040
Why?
Time Factors
2
1999
3047
0.040
Why?
Gastrointestinal Tract
1
2009
26
0.040
Why?
Interleukin-6
1
2011
314
0.040
Why?
Cohort Studies
1
2012
912
0.040
Why?
Jews
2
1996
9
0.040
Why?
Combined Modality Therapy
2
1997
459
0.040
Why?
Kaplan-Meier Estimate
1
2008
190
0.040
Why?
Comorbidity
1
2009
365
0.040
Why?
Young Adult
1
2012
1013
0.040
Why?
Disease Progression
1
2009
496
0.030
Why?
Radiotherapy, Computer-Assisted
1
2006
14
0.030
Why?
Antineoplastic Protocols
1
2006
3
0.030
Why?
Kidney
1
2009
581
0.030
Why?
Emulsions
1
2001
10
0.020
Why?
Skin Pigmentation
1
2001
13
0.020
Why?
Mastectomy, Segmental
1
2001
24
0.020
Why?
Administration, Topical
1
2001
88
0.020
Why?
Antineoplastic Agents, Hormonal
1
2001
44
0.020
Why?
Tamoxifen
1
2001
80
0.020
Why?
Iridium Radioisotopes
1
2000
13
0.020
Why?
Fiber Optic Technology
1
2000
24
0.020
Why?
Postoperative Period
1
2000
78
0.020
Why?
Bronchoscopy
1
2000
27
0.020
Why?
Mitomycin
1
1999
18
0.020
Why?
Ethnic Groups
1
2001
137
0.020
Why?
Bleomycin
1
1999
44
0.020
Why?
Carboplatin
1
1999
29
0.020
Why?
Infusions, Intravenous
1
1999
139
0.020
Why?
Administration, Oral
1
2000
302
0.020
Why?
Arabs
1
1998
2
0.020
Why?
Radiotherapy, Adjuvant
1
1999
72
0.020
Why?
Incidence
1
2001
644
0.020
Why?
Immunocompromised Host
1
1998
84
0.020
Why?
Radiotherapy, High-Energy
1
1997
22
0.020
Why?
Vincristine
1
1997
57
0.020
Why?
Neoplasms, Multiple Primary
1
1997
39
0.020
Why?
Methotrexate
1
1997
73
0.020
Why?
Cyclophosphamide
1
1997
169
0.020
Why?
Doxorubicin
1
1997
102
0.020
Why?
Sunlight
1
1996
14
0.020
Why?
Dose-Response Relationship, Drug
1
1999
1085
0.020
Why?
Practice Guidelines as Topic
1
1999
288
0.020
Why?
Sex Distribution
1
1996
142
0.020
Why?
Age Distribution
1
1996
201
0.020
Why?
Registries
1
1996
203
0.020
Why?
Adolescent
1
1999
4513
0.010
Why?

Visualizations


Katz's Networks

Concepts
_
Co-Authors
_
Same Department